These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 37654961)

  • 1. Current Status of Endothelin Receptor Antagonists in Pulmonary Arterial Hypertension: A Combined Study Results and Pharmacology-Based Review.
    Nahar S; Kanda S; Chatha U; Odoma VA; Pitliya A; AlEdani EM; Bhangu JK; Javed K; Manshahia PK; Yu AK
    Cureus; 2023 Jul; 15(7):e42748. PubMed ID: 37654961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells.
    Gatfield J; Mueller Grandjean C; Sasse T; Clozel M; Nayler O
    PLoS One; 2012; 7(10):e47662. PubMed ID: 23077657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Focus on Macitentan in the Treatment of Pulmonary Arterial Hypertension.
    Bedan M; Grimm D; Wehland M; Simonsen U; Infanger M; Krüger M
    Basic Clin Pharmacol Toxicol; 2018 Aug; 123(2):103-113. PubMed ID: 29719121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Clinical Efficacy of Endothelin Receptor Antagonists in Patients with Pulmonary Arterial Hypertension.
    Maki H; Hara T; Tsuji M; Saito A; Minatsuki S; Inaba T; Amiya E; Hosoya Y; Hatano M; Morita H; Yao A; Kinugawa K; Komuro I
    Int Heart J; 2020; 61(4):799-805. PubMed ID: 32728000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy and safety of endothelin receptor antagonists combined with phosphodiesterase 5 inhibitor in the treatment of pulmonary arterial hypertension: a network meta-analysis].
    Fu WH; Chen PL; Xia JL; Fu L; Shen Y; He WJ; Chen YH; Ren N; Jiang Q; Ma R; Wang T; Wang XN; Zhang NF; Liu CL
    Zhonghua Jie He He Hu Xi Za Zhi; 2022 Feb; 45(2):158-170. PubMed ID: 35135085
    [No Abstract]   [Full Text] [Related]  

  • 6. Safety and tolerability of bosentan in the management of pulmonary arterial hypertension.
    Roberts KE; Preston IR
    Drug Des Devel Ther; 2009 Sep; 3():111-8. PubMed ID: 19920927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the combination of endothelin receptor antagonists (ERA) and phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension (PAH) in pathologic human pulmonary arteries in an ex-vivo organ bath model.
    Englert L; Stadlbauer C; Spaeth M; Hofmann HS; Schneider C; Hatz RA; Preissler G; Michel S; Golovchenko S; Ried M; Hoenicka M
    Pulm Pharmacol Ther; 2021 Feb; 66():101985. PubMed ID: 33359621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic Review of Randomized Controlled Trials of Endothelin Receptor Antagonists for Pulmonary Arterial Hypertension.
    Kuntz M; Leiva-Juarez MM; Luthra S
    Lung; 2016 Oct; 194(5):723-32. PubMed ID: 27506903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis.
    Dranitsaris G; Mehta S
    Appl Health Econ Health Policy; 2009; 7(1):43-59. PubMed ID: 19558194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A network meta-analysis for safety of endothelin receptor antagonists in pulmonary arterial hypertension.
    Zhang YJ; Wang N; Gu ZC; Wei AH; Cheng AN; Fang SS; Du HL; Wang LZ; Zhang GQ
    Cardiovasc Diagn Ther; 2019 Jun; 9(3):239-249. PubMed ID: 31275814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of switching from bosentan or ambrisentan to macitentan in pulmonary arterial hypertension: A systematic review and meta-analysis.
    Li J; Yang ZY; Wang S; Yuan P; Zhao QH; Gong SG; Qiu HL; Luo CJ; Li HT; Zhang R; Wu WH; Liu JM; Wang L; Liu SS; Jiang R
    Front Cardiovasc Med; 2022; 9():977110. PubMed ID: 36568539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension.
    Steiner MK; Preston IR
    Vasc Health Risk Manag; 2008; 4(5):943-52. PubMed ID: 19183742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to scleroderma.
    Kabunga P; Coghlan G
    Drugs; 2008; 68(12):1635-45. PubMed ID: 18681488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of pulmonary arterial hypertension with the dual endothelin receptor antagonist macitentan: clinical evidence and experience.
    Belge C; Delcroix M
    Ther Adv Respir Dis; 2019; 13():1753466618823440. PubMed ID: 30736726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension.
    Dingemanse J; Sidharta PN; Maddrey WC; Rubin LJ; Mickail H
    Expert Opin Drug Saf; 2014 Mar; 13(3):391-405. PubMed ID: 24261583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy and acceptability of endothelin receptor antagonists for pulmonary arterial hypertension: A network meta-analysis.
    Duo-Ji MM; Long ZW
    Int J Cardiol; 2017 May; 234():90-98. PubMed ID: 28233631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution of Patients with Pulmonary Arterial Hypertension Starting Macitentan After the Discontinuation of Other Endothelin-Receptor Antagonists: Results of a Retrospective Study.
    Cadenas-Menéndez S; Álvarez Vega P; Oterino Manzanas A; Alonso Lecue P; Roig Figueroa V; Bedate Díaz P; Ortiz de Saracho J; Cifrián Martínez JM
    Am J Cardiovasc Drugs; 2020 Oct; 20(5):481-487. PubMed ID: 31879844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Adverse Effects of Endothelin Receptor Antagonists: Insights From the Meta-Analysis of 4894 Patients From 24 Randomized Double-Blind Placebo-Controlled Clinical Trials.
    Wei A; Gu Z; Li J; Liu X; Wu X; Han Y; Pu J
    J Am Heart Assoc; 2016 Oct; 5(11):. PubMed ID: 27912207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of ambrisentan in the management of pulmonary hypertension.
    Hrometz SL; Shields KM
    Ann Pharmacother; 2008 Nov; 42(11):1653-9. PubMed ID: 18957622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma Drug Concentrations in Patients with Pulmonary Arterial Hypertension on Combination Treatment.
    Grünig E; Ohnesorge J; Benjamin N; Burhenne J; Enderle Y; Egenlauf B; Fischer C; Harutyunova S; Huppertz A; Klose H; Haefeli WE
    Respiration; 2017; 94(1):26-37. PubMed ID: 28494463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.